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To the editor,
Myeloproliferative neoplasms (MPN) are characterized by a clonal
expansion of mature blood cells and mainly include 3 diseases: poly-
cythemia vera (PV), essential thrombocythemia (ET) and primary
myeloﬁbrosis (PMF). Their diagnosis has been simpliﬁed by the dis-
covery of driver mutations (JAK2V617F, MPL and CALR) that allow
detection of a molecular marker in more than 80% of cases. First de-
scribed in 2005, the JAK2V617F mutation is found in more than 96% of
PV and around half of ET and PMF. Mutations of JAK2 exon 12 andMPL
gene may also, rarely, be found in PV and TE or MPF, respectively. In
2013, a novel type of mutations aﬀecting the CALR gene was described
in JAK2V617F no mutated ET or PMF. CALR gene encodes calreticulin,
a calcium-binding chaperone protein that promotes folding and quality
control in the endoplasmic reticulum. All CALR mutations are insertion
or deletion localized in the exon 9 that result in a frameshift with a
common C-terminal sequence. First described only in ET and PMF,
CALR frameshift mutations were then found in very few patients with
erythrocytosis [1,2]. The mutated protein interacts with MPL receptor
for JAK2/STAT5 pathway activation but not with the erythropoietin
receptor [3]. When introduced in murine hematopoietic cells, it induces
thrombocytosis without erythrocytosis. In a previous report, we iden-
tiﬁed 2 CALR mutated patients within a large cohort of unexplained
polycythemia without JAK2 mutation and reclassiﬁed them as (i) ET
associated to a minimal polycythemia probably induced by chronic
hypoxia and as (ii) an idiopathic erythrocytosis without any clue for
MPN [4]. To date, screening for CALR mutation for the diagnosis of PV
is not advisable and, if such mutation is found, it should not be con-
sidered as a convincing explanation for erythrocytosis.
Here we report a case of an 80-years old man that was referred to
our lab for a chronic thrombocytosis. The patient had a history of heart
arrhythmia and was treated by vitamin K antagonists. The initial ex-
amination showed no splenomegaly, mild leukocytosis (11.9×109/L),
thrombocytosis (902×109/L) and normal hemoglobin and hematocrit
(15.2 g/dL and 44.2% respectively). Nevertheless, a low serum ery-
thropoietin (EPO) level (3.5 UI/L) motivated the measure of red cell
mass that was increased (126%), without evidence for secondary
erythrocytosis. This argues for the usefulness of the red mass measure in
some cases of MPN as previously demonstrated. At the same time a
classical molecular screening found no V617F or exon 12 mutation of
JAK2 but a previously described type 2-like mutation of CALR
(c.1154_1155insATGTC; p.Glu386Cysfs*46; type 33 according Klampﬂ
et al.). To better understand the molecular landscape of this case we
performed a 64-genes custom next generation sequencing (Haloplex HS,
Illumina NextSeq500) that conﬁrmed the CALR mutation with a variant
allele frequency (VAF) of 52%. It was associated to a LNK mutation
(c.639C>A; p.Ser213Arg) with a VAF of 48% that was validated by
Sanger sequencing. This mutation of LNK occurred in the “hotspot” of
the exon 2 coding for the PH domain of the protein and was predicted to
be deleterious by both SIFT, Polyphen2 and MutationTaster tools. The
Ser213Arg mutation of LNK was previously described in a case of JAK2-
negative erythrocytosis without somatic validation (COSM1685386)
[5]. In this previous report the patient had a hemoglobin of 17 g/dL, a
hematocrit of 50.4% and a low EPO level (4 UI/L) as in the patient
reported herein. This LNK variant had a minor allele frequency of
0.063% in gnomAD database (rs111360561). For this reason we con-
trolled the mutation on germinal DNA derived from nails and found
that it was indeed a constitutional variant. LNK (SH2B3) is an adaptor
protein that, after binding, inhibits JAK2 signaling. LNK deﬁcient mice
display marked changes of the hematopoiesis, including splenomegaly
and a great increase of number of hematopoietic progenitors that have
in vitro high proliferative capacities in part due to hypersensitivity to
several cytokines [6]. Most of LNK mutations identiﬁed are missense
mutations and occur predominantly in exon 2 coding for the PH domain
of LNK. LNK mutations were found in MPN, especially at leukemic
transformation and in idiopathic erythrocytosis (IE) [7]. In particular
the mutation Glu208Gln, which is located near the mutation described
herein, can be found in both MPN and IE and had a minor allele fre-
quency of 0.099% in gnomAD database.
We therefore retained the diagnosis of CALR-mutated ET associated
to a LNK-mutated constitutional mild erythrocytosis. Bone marrow
biopsy was not feasible because of oral anticoagulation. The exclusion
of PMF was based on absence of tear drop cells on the blood smear and
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a normal circulating CD34 cells count at 2/μL [8]. A treatment by hy-
droxycarbamide was started with a complete clinicohematological re-
sponse at 18months of follow-up.
This report emphasizes the interest of a NGS research for other
mutations (such LNK or non-V617F JAK2 mutations) when CALR MPN
is associated to erythrocytosis. Other causes of erythrocytosis as high
oxygen-aﬃnity hemoglobin, R-EPO mutations or pathologic EPO pro-
duction by tumors should also be considered in such cases.
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